Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers

被引:1
|
作者
Picton, Anabela C. P. [1 ]
Paximadis, Maria [1 ,2 ]
Koor, Gemma W. [1 ,2 ]
Bharuthram, Avani [1 ,2 ]
Shalekoff, Sharon [1 ,2 ]
Lassauniere, Ria [3 ]
Ive, Prudence [2 ,4 ]
Tiemessen, Caroline T. [1 ,2 ]
机构
[1] Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa
[2] Univ Witwatersrand, Sch Pathol, Dept Virol, Fac Hlth Sci, Johannesburg, South Africa
[3] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Virus Res & Dev Lab, Copenhagen, Denmark
[4] Univ Witwatersrand, Sch Clin Med, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
HIV-1; control; CCR5; expression; immune activation; ligands; IL-10; IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ACTIVATION; SERUM CHEMOKINE LEVELS; BETA-CHEMOKINES; DISEASE PROGRESSION; PLASMA-LEVELS; CELL SUBSETS; SOLUBLE CD14; INFECTION; SUSCEPTIBILITY;
D O I
10.3389/fimmu.2021.781263
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Unique Individuals who exhibit either suppressive HIV-1 control, or the ability to maintain low viral load set-points and preserve their CD4+ T cell counts for extended time periods in the absence of antiretroviral therapy, are broadly termed HIV-1 controllers. We assessed the extent to which black South African controllers (n=9), differ from uninfected healthy controls (HCs, n=22) in terms of lymphocyte and monocyte CCR5 expression (density and frequency of CCR5-expressing cells), immune activation as well as peripheral blood mononuclear cell (PBMC) mitogen-induced chemokine/cytokine production. In addition, relative CD4+ T cell CCR5 mRNA expression was assessed in a larger group of controllers (n=20) compared to HCs (n=10) and HIV-1 progressors (n=12). Despite controllers having significantly higher frequencies of activated CD4+ and CD8+ T cells (HLA-DR+) compared to HCs, CCR5 density was significantly lower in these T cell populations (P=0.039 and P=0.064, respectively). This lower CCR5 density was largely attributable to controllers with higher VLs (>400 RNA copies/ml). Significantly lower CD4+ T cell CCR5 density in controllers was maintained (P=0.036) when HCs (n=12) and controllers (n=9) were matched for age. CD4+ T cell CCR5 mRNA expression was significantly less in controllers compared to HCs (P=0.007) and progressors (P=0.002), whereas HCs and progressors were similar (P=0.223). The levels of soluble CD14 in plasma did not differ between controllers and HCs, suggesting no demonstrable monocyte activation. While controllers had lower monocyte CCR5 density compared to the HCs (P=0.02), significance was lost when groups were age-matched (P=0.804). However, when groups were matched for both CCR5 promoter haplotype and age (n=6 for both) reduced CCR5 density on monocytes in controllers relative to HCs was highly significant (P=0.009). Phytohemagglutinin-stimulated PBMCs from the controllers produced significantly less CCL3 (P=0.029), CCL4 (P=0.008) and IL-10 (P=0.028) compared to the HCs, which was largely attributable to the controllers with lower VLs (<400 RNA copies/ml). Our findings support a hypothesis of an inherent (genetic) predisposition to lower CCR5 expression in individuals who naturally control HIV-1, as has been suggested for Caucasian controllers, and thus, likely involves a mechanism shared between ethnically divergent population groups.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
    Putcharoen, O.
    Lee, S-H
    Henrich, T. J.
    Vanichanan, J.
    Kuritzkes, D. R.
    Tsibris, A. M. N.
    ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
  • [22] Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/Delta 32ccr5 heterozygotes
    Edelstein, RE
    Arcuino, LAM
    Hughes, JP
    Melvin, AJ
    Mohan, KM
    King, PD
    McLellan, CL
    Murante, BL
    Kassman, BP
    Frenkel, LM
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (04): : 243 - 246
  • [23] Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor
    Mirzabekov, T
    Bannert, N
    Farzan, M
    Hofmann, W
    Kolchinsky, P
    Wu, LJ
    Wyatt, R
    Sodroski, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (40) : 28745 - 28750
  • [24] Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
    Mohamed, Hager
    Gurrola, Theodore
    Berman, Rachel
    Collins, Mackenzie
    Sariyer, Ilker K.
    Nonnemacher, Michael R.
    Wigdahl, Brian
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [25] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [26] CCR5 genotype and resistance to vertical transmission of HIV-1
    Philpott, S
    Burger, H
    Charbonneau, T
    Grimson, R
    Vermund, SH
    Visosky, A
    Nachman, S
    Kovacs, A
    Tropper, P
    Frey, H
    Weiser, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193
  • [27] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [28] CCR5 promoter polymorphism and HIV-1 disease progression
    McDermott, DH
    Zimmerman, PA
    Guignard, F
    Kleeberger, CA
    Leitman, SF
    Murphy, PM
    LANCET, 1998, 352 (9131): : 866 - 870
  • [29] CCR5, vertical transmission of HIV-1, and disease progression
    Bailey, AJ
    Newell, ML
    De Rossi, A
    Giaquinto, C
    Iasci, A
    Ravizza, M
    Garcia-Rodriguez, MC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (02): : 211 - 212
  • [30] The promise of CCR5 antagonists as new therapies for HIV-1
    Repik, Alexander
    Richards, Kathryn H.
    Clapham, Paul R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139